Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Cyclophosphamide with Cisplatin/Etoposide in ES-SCLC
NCT00083161Phase 2Completed
- Sponsor
- Gundersen Health System
- Start
- Jun 2003
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in small cell lung cancer (SCLC), sponsored by Gundersen Health System. Primary endpoints: Safety and Effect of metronomic chemotherapy on circulating endothelial cells. Started Jun 2003; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00083161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083161.